These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18292526)

  • 1. Prophylactic treatment with fms-like tyrosine kinase-3 ligand after burn injury enhances global immune responses to infection.
    Bohannon J; Cui W; Cox R; Przkora R; Sherwood E; Toliver-Kinsky T
    J Immunol; 2008 Mar; 180(5):3038-48. PubMed ID: 18292526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous Fms-like tyrosine kinase-3 ligand levels are not altered in mice after a severe burn and infection.
    Bohannon JK; Cui W; Toliver-Kinsky T
    BMC Immunol; 2009 Aug; 10():47. PubMed ID: 19715582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flt3 Ligand Treatment Attenuates T Cell Dysfunction and Improves Survival in a Murine Model of Burn Wound Sepsis.
    Patil NK; Bohannon JK; Luan L; Guo Y; Fensterheim B; Hernandez A; Wang J; Sherwood ER
    Shock; 2017 Jan; 47(1):40-51. PubMed ID: 27454384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic cell modification of neutrophil responses to infection after burn injury.
    Bohannon J; Cui W; Sherwood E; Toliver-Kinsky T
    J Immunol; 2010 Sep; 185(5):2847-53. PubMed ID: 20679533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fms-like tyrosine kinase-3 ligand increases resistance to burn wound infection through effects on plasmacytoid dendritic cells.
    Bae L; Bohannon JK; Cui W; Vinish M; Toliver-Kinsky T
    BMC Immunol; 2017 Feb; 18(1):9. PubMed ID: 28228109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of dendritic cell production by fms-like tyrosine kinase-3 ligand increases the resistance of mice to a burn wound infection.
    Toliver-Kinsky TE; Cui W; Murphey ED; Lin C; Sherwood ER
    J Immunol; 2005 Jan; 174(1):404-10. PubMed ID: 15611264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fms-Like Tyrosine Kinase-3 Ligand Attenuates Local and Systemic Infection in a Model of Post-Burn Pneumonia.
    Hundeshagen G; Cui W; Musgrove L; Cherry A; Lee SJ; Cox RA; Toliver-Kinsky T
    Shock; 2018 Jun; 49(6):721-727. PubMed ID: 28796661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fms-like tyrosine kinase-3 ligand alters antigen-specific responses to infections after severe burn injury.
    Bohannon J; Fang G; Cui W; Sherwood E; Toliver-Kinsky T
    Shock; 2009 Oct; 32(4):435-41. PubMed ID: 19752689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-15 Superagonist Expands mCD8+ T, NK and NKT Cells after Burn Injury but Fails to Improve Outcome during Burn Wound Infection.
    Patil NK; Luan L; Bohannon JK; Guo Y; Hernandez A; Fensterheim B; Sherwood ER
    PLoS One; 2016; 11(2):e0148452. PubMed ID: 26859674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of hematopoiesis by the Fms-like tyrosine kinase 3 ligand restores bacterial induction of Th1 cytokines in thermally injured mice.
    Toliver-Kinsky TE; Lin CY; Herndon DN; Sherwood ER
    Infect Immun; 2003 Jun; 71(6):3058-67. PubMed ID: 12761083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective expansion of merocytic dendritic cells and CD8DCs confers anti-tumour effect of Fms-like tyrosine kinase 3-ligand treatment in vivo.
    Hennies CM; Reboulet RA; Garcia Z; Nierkens S; Wolkers MC; Janssen EM
    Clin Exp Immunol; 2011 Mar; 163(3):381-91. PubMed ID: 21235535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart, but not skin, allografts from donors lacking Flt3 ligand exhibit markedly prolonged survival time.
    Wang Z; Castellaneta A; De Creus A; Shufesky WJ; Morelli AE; Thomson AW
    J Immunol; 2004 May; 172(10):5924-30. PubMed ID: 15128773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA-encoded fetal liver tyrosine kinase 3 ligand and granulocyte macrophage-colony-stimulating factor increase dendritic cell recruitment to the inoculation site and enhance antigen-specific CD4+ T cell responses induced by DNA vaccination of outbred animals.
    Mwangi W; Brown WC; Lewin HA; Howard CJ; Hope JC; Baszler TV; Caplazi P; Abbott J; Palmer GH
    J Immunol; 2002 Oct; 169(7):3837-46. PubMed ID: 12244180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y; Huang H; Chen Z; Zong L; Xiang J
    J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo.
    Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH
    J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FMS-like tyrosine kinase 3 ligand treatment of mice aggravates acute lung injury in response to Streptococcus pneumoniae: role of pneumolysin.
    Brumshagen C; Maus R; Bischof A; Ueberberg B; Bohling J; Osterholzer JJ; Ogunniyi AD; Paton JC; Welte T; Maus UA
    Infect Immun; 2012 Dec; 80(12):4281-90. PubMed ID: 23006850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flt3 ligand bioactivity and pharmacology in neoplasia.
    Reber AJ; Ashour AE; Robinson SN; Talmadge JE; Solheim JC
    Curr Drug Targets Immune Endocr Metabol Disord; 2004 Jun; 4(2):149-56. PubMed ID: 15180455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fms-like tyrosine kinase 3 ligand controls formation of regulatory T cells in autoimmune arthritis.
    Svensson MN; Andersson SE; Erlandsson MC; Jonsson IM; Ekwall AK; Andersson KM; Nilsson A; Bian L; Brisslert M; Bokarewa MI
    PLoS One; 2013; 8(1):e54884. PubMed ID: 23349985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment.
    Matsumura N; Mandai M; Hamanishi J; Yamaguchi K; Fukuhara K; Yagi H; Higuchi T; Takakura K; Fujii S
    Oncol Rep; 2008 Feb; 19(2):505-15. PubMed ID: 18202801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology.
    Larocque D; Sanderson NS; Bergeron J; Curtin JF; Girton J; Wibowo M; Bondale N; Kroeger KM; Yang J; Lacayo LM; Reyes KC; Farrokhi C; Pechnick RN; Castro MG; Lowenstein PR
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14443-8. PubMed ID: 20660723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.